Literature DB >> 11845015

Coronary artery disease and rheumatoid arthritis.

Nicola Goodson1.   

Abstract

Patients with rheumatoid arthritis (RA) have a reduced life expectancy when compared with the general population. Cardiovascular death is considered the leading cause of mortality in patients with RA; it is responsible for approximately half the deaths observed in RA cohorts. The prevalence of cardiovascular comorbidity is difficult to assess accurately, because cardiovascular disease (CVD) has a tendency to remain silent in the rheumatoid patient. It is not clear why rheumatoid patients have higher rates of coronary disease. Traditional cardiovascular risk factors do not seem to be wholly responsible for the increased cardiovascular risk. Novel cardiovascular risk factors, including inflammatory markers, have been identified over the past few years. It may be that these new cardiovascular risk factors are responsible for accelerating coronary heart disease in patients with RA. This article reviews recent literature relating to the epidemiology of cardiovascular disease in the context of RA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11845015     DOI: 10.1097/00002281-200203000-00007

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  31 in total

1.  Long term safety of etanercept in elderly subjects with rheumatic diseases.

Authors:  R Fleischmann; S W Baumgartner; M H Weisman; T Liu; B White; P Peloso
Journal:  Ann Rheum Dis       Date:  2005-09-08       Impact factor: 19.103

Review 2.  [Rheumatoid arthritis and cardiovascular complications].

Authors:  W Seidel; M Hecker; U Wagner; H Häntzschel
Journal:  Z Rheumatol       Date:  2006-10       Impact factor: 1.372

3.  Estimating SNP-Based Heritability and Genetic Correlation in Case-Control Studies Directly and with Summary Statistics.

Authors:  Omer Weissbrod; Jonathan Flint; Saharon Rosset
Journal:  Am J Hum Genet       Date:  2018-07-05       Impact factor: 11.025

4.  Preliminary Report of Endovascular Treatment for Critical Limb Ischemia Patients with Connective Tissue Disease: Cases Series and Review of the Literature.

Authors:  Hideaki Obara; Kentaro Matsubara; Naoki Fujimura; Yasuhito Sekimoto; Yuko Kitagawa
Journal:  Int J Angiol       Date:  2015-06

5.  Proteolysis of apolipoprotein A-I by secretory phospholipase A₂: a new link between inflammation and atherosclerosis.

Authors:  Giorgio Cavigiolio; Shobini Jayaraman
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

6.  Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome.

Authors:  K M J Douglas; A V Pace; G J Treharne; A Saratzis; P Nightingale; N Erb; M J Banks; G D Kitas
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

7.  Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study.

Authors:  P C Souverein; A Berard; T P Van Staa; C Cooper; A C G Egberts; H G M Leufkens; B R Walker
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

8.  Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis.

Authors:  Laura Bazzichi; Lorenzo Ghiadoni; Alessandra Rossi; Melania Bernardini; Mario Lanza; Francesca De Feo; Camillo Giacomelli; Ilaria Mencaroni; Katia Raimo; Marco Rossi; Anna Maria Mazzone; Stefano Taddei; Stefano Bombardieri
Journal:  Mol Med       Date:  2009-06-18       Impact factor: 6.354

9.  [Multimorbidity in elderly rheumatic patients part 1].

Authors:  H-J Lakomek; T Brabant; M Lakomek; D Lüttje
Journal:  Z Rheumatol       Date:  2013-08       Impact factor: 1.372

10.  Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Holly John; Karen M J Douglas; George D Kitas
Journal:  Arthritis Res Ther       Date:  2009-07-16       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.